Related to British Columbia Cancer Agency Added to Illumina Genome Network

• Reporting from J.P. Morgan Healthcare Conference
  Drug companies developing companion diagnostics is just one of the trends highlighted at the meeting.
  
• Human Genome Redux: Just a Numbers Game?
  Success of sequencing capabilities is dependent on tools to analyze the data.
  
• 2010 in Review: Biotechnology Highlights
  Gene patenting and ESCs were back in the headlines along with breakthroughs in sequencing, syn bio, and other fields.
  
• Biotechs Nail Down Sequence of Elusive E. coli
  A new hybrid strain is responsible for the European outbreak that’s been all over the news.
  
• Product and Service Firms Challenged by Uncertain NIH Funding, Polarization of Sequencing
  Analysts and vendors are preparing for low to no growth in 2012 and 2013.
  
• Exome Sequencing Finds Sweet Spot Between Whole-Genome and Targeted Sequencing
  Technique provides a cost-effective tool for dissecting diseases that have been intractable to conventional gene discovery.
  
• Standardization Key to Taking Next-Generation Sequencing to the Next Level
  As NGS technology makes steady progress with faster and cheaper machines, regulation will have to keep up.
  
• Academic Sequencing Centers May Feel the Pinch of Budgetary Constraints and Data Deluge
  NHGRI renewed $416 million over four years in funding for three centers but warned of lower funds in the future.
  
• Presidential Panel Wrestles with Ethical Issues Linked to Clinical Use of Whole Genome Sequencing
  Final recommendations, to be presented this fall, will encompass technology delivery and informed consent.
  
• Sequencing in the Dark
  Analysis of Life Technologies’ Ion Torrent sequencing platform points to significance of photon-free technology.
  
• Roche, Illumina Duke It Out in Potential $5.7B Takeover Deal
  Roche’s hostile $44.50 per share bid could also spark additional sequencing acquisition wars.
  
• U.K. Groups Grapple with Ethical Issues Linked to Clinical Sequencing
  Questions cover data dissemination, bioinformatics, and more education.
  
• Moving Genomics Closer to the Clinic
  Foundation Medicine and Memorial Sloan-Kettering Cancer Center are working to translate genomic information into personalized cancer treatment.
  
• R&D Direction in 2012 for Sequencing Technologies Is Aimed at Clinical Medicine
  Companies are focused on making these platforms smaller and easier to use.
  
• Will Roche Really Drop Illumina and Seek out Another Sequencing Firm?
  Oxford Nanopore and PacBio both have exciting technologies, but Illumina remains market leader.
  
• Illumina, Complete Genomics Prepare for Legal Battle over Sequencing IP
  Illumina filed the case stating that the Complete Genomics Analysis Platform infringes on three of its patents.
  
• Sequencing Firms Set Up Centers to Advance Genomics Research and Instrument Sales
  Strategy provides a feedback loop to improve instrumentation and develop new applications.